iRECIST · Oncologia

iRECIST iRECIST for immunotherapy response

vigente

Adapts RECIST for atypical immunotherapy response patterns.

Índice de referência, não é suporte à decisão clínica. O RadCommons apresenta conteúdo de referência reescrito a partir de critérios publicados e com link para a fonte primária. Confira sempre a publicação primária vigente. Não é um dispositivo médico nem substitui o julgamento clínico. O radiologista responsável pelo laudo permanece o autor e o responsável.

Escala de categorias

iCR iPR iSD iUPD iCPD

As figuras e tabelas estão na fonte primária. Abrir a fonte. O RadCommons reescreve e cita, não reproduz figuras protegidas por direitos autorais.

Procedência e vigência

Órgão emissor: RECIST Working Group
Versão: 2017
Ano: 2017
Família: léxico
Tipo de lógica: flat
Modalidade: CT, MRI
Fonte primária: iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics · doi:10.1016/S1470-2045(17)30074-8
Última verificação: 2026-06-22
Última checagem: 2026-06-22

Lógica de decisão

Forma estruturada (flat). Uma futura calculadora a lê; as categorias abaixo são a superfície legível.

Mostrar a lógica estruturada (JSON)

{
  "categories": [
    "iCR",
    "iPR",
    "iSD",
    "iUPD",
    "iCPD"
  ]
}

Categorias num relance

Cat.	Significado	Conduta	Risco	Fonte
iCR	Immune complete response Immune Complete Response: complete disappearance of all target and non-target lesions, with every lymph node regressing to a non-pathological short axis below 10 mm.	—	—	okfonte PMC6942293 (Persigehl, Lennartz & Schwartz, 'iRECIST: how to do it', Cancer Imaging 2020) section 'Responses to therapy' ('Complete disappearance of TL and Non-TL. All lymph nodes must be non-pathological in size (<10 mm in SAD)')
iPR	Immune partial response Immune Partial Response: at least a 30% reduction in the target-lesion tumor burden versus baseline (or, when target lesions have fully resolved, one or more non-target lesions remain detectable).	—	—	okfonte PMC6942293 section 'Responses to therapy' (tumor load of target lesions reduced by >=30% vs baseline; the article's phrasing references the >=30% reduction consistent with RECIST 1.1 PR)
iSD	Immune stable disease Immune Stable Disease: criteria for iCR or iPR are not met and no progression is present.	—	—	okfonte PMC6942293 section 'Responses to therapy' ('Determined if the criteria of iCR or iPR are not met and no tumor progression is present')
iUPD	Immune unconfirmed progression Immune Unconfirmed Progressive Disease: a first detection of progression — at least a 20% rise in the sum of target lesions (and at least 5 mm absolute) versus nadir, or unequivocal non-target progression, or the appearance of new lesions. Because of possible pseudoprogression it is NOT yet confirmed and requires reassessment, typically after 4-8 weeks.	—	—	okfonte PMC6942293 section 'Responses to therapy' ('Increase in the sum of all TL by at least >=20% (but at least >=5 mm) compared to Nadir, or unequivocal progression of Non-TL, or occurrence of new measurable/non-measurable tumor lesions'); confirmation timing 'Earlier follow-up after 4-8 weeks, in contrast to regularly recommended 6-12 weeks'
iCPD	Immune confirmed progression Immune Confirmed Progressive Disease: progression confirmed at the follow-up scan after a prior iUPD, shown by further growth of the target-lesion sum (at least 5 mm more), any further increase in non-target disease, or progression of new lesions (increase in number or in size, sum at least 5 mm). If nothing worsens further, the patient stays at iUPD rather than progressing to iCPD.	—	—	okfonte PMC6942293 section 'Responses to therapy' ('Further progress of the target sum (>=5 mm), or any further progress of the Non-TL, and/or progress of new measurable and non-measurable lesions either in number or in size (sum >=5 mm)'; 'If progression not confirmed and TL, Non-TL and new lesions remain unchanged, iUPD status should be kept')

Referências cruzadas

fronteira compartilhadaRECIST 1.1. Response Evaluation Criteria in Solid Tumours v1.1iRECIST adapts RECIST 1.1 for immunotherapy response patterns.

Histórico de versões

Data	Evento	Detalhe	Situação
2017-03-01	published	iRECIST guideline published.	confirmado

Quickstart da APIGET /api/v1/systems/irecistaberto

curl -s "https://radcommons.laudos.ai/api/v1/systems/irecist"

Ver documentação completa →